Overview

Study of the KPCXM18 Injection for Treatment of Acute Ischemic Stroke

Status:
Not yet recruiting
Trial end date:
2024-07-30
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, double-blind, parallel, placebo-controlled trial design to evaluate the efficacy and safety of the KPCXM18 injection at different doses for the treatment of acute ischemic stroke and its PK/PD characteristics in patients.
Phase:
Phase 2
Details
Lead Sponsor:
Kunming Pharmaceuticals, Inc.